PMID: 6537893Feb 15, 1984Paper

Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity

Cancer
P SalemL Hashimi

Abstract

Ninety-six cancer patients received a total of 280 courses of cis-diamminedichloroplatinum (DDP), alone (20 patients), or in combination with other agents. DDP was given in 20 mg/m2 as a continuous 24-hour infusion daily for 5 consecutive days, repeated every 4 to 6 weeks. Patients were adequately hydrated for 12 hours prior to treatment but no diuretics or mannitol were used. Twenty percent of the patients developed no toxicity. Nausea and vomiting were lacking in 42% of 256 evaluable cycles and were mild in 36%. Nephrotoxicity was observed in four patients (5%) and was reversible on cessation of therapy in all except one. Hypomagnesemia occurred in 4% of 140 evaluable cycles. Mild ototoxicity was noted in two patients. The therapeutic efficacy of this dose schedule could not be adequately assessed, but one patient with thymoma and extensive pulmonary metastases achieved partial remission on DDP alone, and another with progressive mediastinal thymoma achieved stabilization of disease. In conclusion, this study suggests that the toxicity of the 5-day continuous infusion regimen is relatively mild. Randomized trials are indicated to evaluate the therapeutic efficacy of this new regimen, and the role of DDP in the treatment of ma...Continue Reading

Citations

Jan 1, 1995·Cancer Chemotherapy and Pharmacology·M P GoslandW J John
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·V PinzaniP Balmès
Jan 1, 1993·Journal of Cancer Research and Clinical Oncology·Z H SiddikA R Khokhar
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·Z H SiddikA R Khokhar
Mar 5, 2008·Cancer Chemotherapy and Pharmacology·Vincent Launay-VacherUNKNOWN European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Mar 1, 1989·Toxicology Letters·J P Fillastre, G Raguenez-Viotte
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P H HilkensM J van den Bent
Jan 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J van den BentM E L van der Burg
Feb 19, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BoniA Zadro
Jan 1, 1987·Cancer Drug Delivery·S M GrunbergM L Apuzzo
Apr 1, 1996·American Journal of Clinical Oncology·S C RemickG R Harper
Feb 8, 2006·Journal of Pediatric Hematology/oncology·Abha A GuptaSheila Weitzman
Jul 28, 2011·Journal of Pediatric Hematology/oncology·Ponni SivaprakasamPaul C Nathan
Oct 1, 1992·Journal of Clinical Pharmacy and Therapeutics·E RochardP Courtois
Sep 1, 1994·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P H HilkensM J van den Bent
Aug 27, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jacob Atsmon, Eran Dolev
Mar 28, 2003·Neoplasia : an International Journal for Oncology Research·Ardith W El-Kareh, Timothy W Secomb
Nov 1, 1987·European Journal of Cancer & Clinical Oncology·M Bues-CharbitC Raybaud
Jan 1, 1990·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·N TinkerJ P Reman
Apr 1, 1991·The Journal of Pediatrics·P R BrockJ Pritchard
Jun 1, 1997·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·U MetzgerF Largiadèr
Sep 1, 1991·Cancer·C M LindleyS J Tremont
Sep 25, 1999·British Journal of Cancer·M W EnglishA W Craft
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P E Kintzel
May 1, 1985·Drug Intelligence & Clinical Pharmacy·R S FinleyW R Grove
Jul 1, 1996·Renal Failure·C DonadioA Gadducci

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.